Overweight Clinical Trials in Orlando, Florida

12 studies are recruiting for overweight in Orlando, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

   Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesity or overweight wit…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Charter Research - Winter Park /ID# 281968, Orlando, Florida

   Locations

   64 in total

   Run by

   AbbVie

   See if you can join NCT07752979 on ClinicalTrials.gov

2. A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

   The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will …

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Charter Research - Winter Park, Orlando, Florida

   Locations

   40 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07589608 on ClinicalTrials.gov

3. A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

   This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Headlands Research Orlando, Orlando, Florida

   Locations

   180 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07794579 on ClinicalTrials.gov

4. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

   The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newl…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Charter Research - Winter Park, Orlando, Florida

   Locations

   57 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06143956 on ClinicalTrials.gov

5. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

   The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.

   Stage

   Phase 3

   Ages

   6 to 17

   Site

   Florida Hospital- Center for Pediatric Research, Orlando, Florida

   Locations

   116 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06672549 on ClinicalTrials.gov

6. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

   The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).

   Stage

   Phase 3

   Ages

   18 to 99

   Site

   Florida Institute for Clinical Research, Orlando, Florida

   Locations

   45 in total

   Run by

   Amgen

   See if you can join NCT07684144 on ClinicalTrials.gov

7. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

   The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).

   Stage

   Phase 3

   Ages

   18 to 99

   Site

   Clinical Neuroscience Solutions - Orlando, Orlando, Florida

   Locations

   92 in total

   Run by

   Amgen

   See if you can join NCT07684235 on ClinicalTrials.gov

8. Comparing the Efficacy and Safety of the EndoZip System and Apollo ESG in Obese Patients

   evaluation of the EndoZip system procedure compared to the Apollo ESG procedure in obese patients.

   Stage

   Not phased

   Ages

   21 to 65

   Site

   Orlando Health, Inc., Orlando, Florida

   Locations

   5 in total

   Run by

   Nitinotes Surgical Ltd.

   See if you can join NCT07090005 on ClinicalTrials.gov

9. A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide

   The primary objective of the study is to estimate the PK parameters of ribupatide in participants with severe renal impairment or end-stage kidney disease (ESKD) after a single dose of ribupatide subcutaneous (SC) injection compared with participants with normal renal function.

   Stage

   Phase 1

   Ages

   18 to 85

   Site

   Kailera Clinical Site, Orlando, Florida

   Locations

   2 in total

   Run by

   Kailera

   See if you can join NCT07793929 on ClinicalTrials.gov

10. AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

    The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the trea…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Florida Institute for Clinical Research, LLC, Orlando, Florida

    Locations

    74 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07533175 on ClinicalTrials.gov

11. A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

    The purpose of this study is to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treatment with semaglutide.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Florida Inst For Clin Res LLC, Orlando, Florida

    Locations

    45 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07668414 on ClinicalTrials.gov

12. AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

    The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as oral tablets once a day. Participants will either get zenagamtide (the treatment being tested) or Placebo (trea…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Clinical Neuroscience Solution, Orlando, Florida

    Locations

    41 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07720271 on ClinicalTrials.gov